Meeting
2019 ASCO Annual Meeting
Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275.
Authors
Arlene O. Siefker-Radtke
The University of Texas MD Anderson Cancer Center, Houston, TX
Arlene O. Siefker-Radtke , Ari David Baron , Andrea Necchi , Elizabeth R. Plimack , Sumanta K. Pal , Jens Bedke , Yousef Zakharia , Marc-Oliver Grimm , Sergio Bracarda , Margitta Retz , Chikara Ohyama , Gary Grossfeld , Sandra Collette , Padmanee Sharma , Matt D. Galsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Bladder Cancer
Clinical Trial Registration Number
NCT02387996
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4524)
DOI
10.1200/JCO.2019.37.15_suppl.4524
Abstract #
4524
Poster Bd #
350
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Livmoniplimab with or without budigalimab in patients with advanced solid tumors: Results from the combination therapy in the urothelial carcinoma dose expansion cohort.
First Author: Desamparados Roda
Poster
2019 Genitourinary Cancers Symposium
Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma (RCC): Results from the phase IIIb/IV CheckMate 374 study.
First Author: Nicholas J. Vogelzang
Poster
2019 ASCO Annual Meeting
Efficacy and safety of pembrolizumab in patients with advanced adrenocortical carcinoma.
First Author: Nitya Prabhakar Raj
Poster
2018 ASCO Annual Meeting
Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.
First Author: Ronan Joseph Kelly